Variability in the P6gag domains of HIV-1 involved in viral budding

AIDS

Volumn 20, Issue 4, 2006, Pages 624-627

  Holguín, África ^a   Alvarez, Amparo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AIP1 PROTEIN, HUMAN; DNA BINDING PROTEIN; GAG PROTEIN; PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE SEQUENCE; GENETIC VARIABILITY; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; SEQUENCE ANALYSIS; VIROGENESIS; VIRUS CELL INTERACTION; BINDING SITE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; PHYSIOLOGY; VIRUS REPLICATION;

BINDING SITES; DNA-BINDING PROTEINS; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PROTEINS; TRANSCRIPTION FACTORS; VARIATION (GENETICS); VIRUS REPLICATION;

EID: 33645410524     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210619.75707.21     Document Type: Article

References (32)

1. Freed E. HIV-1 and the host cell: an intimate association. Trends Microbiol 2004; 12:170-177.
2. Gottlinger H, Dorfman T, Sodroski J, Haseltine W. Effect of mutations affecting the P6 gag protein on HIV particle release. Proc Natl Acad Sci U S A 1991; 88:3195-3199.
3. Garrus J, von Schwedler U, Pornillos O, Morham SG, Zavitz KH, Wang HE, et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107:55-65.
4. Goff A, Ehrlich S, Cohen S, Carter C. Tsg101 control of HIV-1 Gag trafficking and release. J Virol 2003; 77:9173-9182.
5. Strack B, Calistri A, Craig S, Popova E, Göttlinger HG. AIP1/ ALIX is a binding partner for HIV-1 P6 and EIAV P9 functioning in virus budding. Cell 2003; 114:689-699.
6. Gottlinger H. The HIV-1 assembly machine. AIDS 2001; 15 (Suppl. 5):S13-S20.
7. Martín-Serrano J, Pérez-Caballero D, Bieniasz P. Context-dependent effects of L domains and ubiquitination on viral budding. J Virol 2004; 78:5554-5563.
8. Demirov D, Orenstein J, Freed E. The late domain of HIV-1 P6 promotes virus release in a cell type-dependent manner. J Virol 2002; 76:105-117.
9. Martín-Serrano J, Zang T, Bieniasz P. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particles assembly to facilitate egress. Nat Med 2001; 7:1313-1319.
10. Pornillos O, Garrus J, Sundquist W. Mechanisms of envelope RNA virus budding. Trend Cell Biol 2002; 12:569-579.
11. Kuiken C, Foley B, Hahn B, Marx P, McCutchon F, Mellors J, et al. HIV sequence compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group. Los Alamos National Laboratory; 2001.
12. Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 2003; 17:2547-2560.
13. Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: HIV sequence compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2000. pp. 54-72.
14. Baldrich-Rubio E, Anagonou S, Stirrups K, Lafia E, Candotti D, Lee H, Allain JP. A complex HIV type 1 A/G/J recombinant virus isolated from a seronegative patient with AIDS from Benin. West Africa J Gen Virol 2001; 82:1095-1106.
15. Candotti D, Adu-Sarkodie Y, Davies F, Baldrich-Rubio E, Stirrups H, Allain J. AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection. J Med Virol 2000; 62:1-8.
16. Jenny-Avital E, Beatrice S. Erroneously low or undetectable plasma HIV-1 RNA load, determined by PCR, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis 2001; 32:1227-1230.
17. Descamps D, Apetrei C, Collin C, Damond F, Simon F, Brun-Vézinet F. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12:1109-1111.
18. Holguín A, Soriano V. Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. HIV Clin Trials 2002; 3:403-411.
19. Loemba H, Brenner B, Parniak M, Ma'ayan S, Spira B, Moisi D, et al. Genetic divergence of HIV type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46:2087-2094.
20. Peters S, Muñoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, et al. Resistance to analog reverse transcriptase inhibitors mediated by HIV-1 P6 protein. J Virol 2001; 75:9644-9653.
21. Velazquez-Campoy A, Vega S, Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 2002; 41:8613-8619.
22. Holguín A, Alvarez A, Soriano V. Differences in Gag proteins length across different HIV-1 subtypes. AIDS Res Hum Retroviruses 2005; 21:886-893.
23. Marlowe N, Flys T, Hackett J, Schumaker M, Brooks Jackson J, Eshleman S. Analysis of insertions and deletions in the gag p6 region of diverse HIV-1 strains. AIDS Res Hum Retroviruses 2004; 20:1119-1125.
24. Kaufmann G, Suzuki K, Cunningham P, Mukaide M, Kondo M, Imai M, et al. Impact of HIV-1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses 2001; 17:487-497.
25. Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, et al. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. Antiviral Ther 2004; 9:221-227.
26. gag N-terminal region in drug-naive individuals initiating antiretroviral therapy. Antiviral Ther 2003; 8:91-96.
27. Gallego O, de Mendoza C, Corral A, Soriano V. Changes in HIV-1 p7/p1/p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol 2003; 41:1245-1247.
28. Lastere S, Perrin V, Dam E, Brun-Vezinet F, Mammano F. Replicative capacity and drug susceptibility of viral clones carrying duplication of the PTAPP motif in wild-type and drug-resistant PR-RT contexts. Antiviral Ther 2005; 10:S174.
29. Von Schewdler U, Stuchell M, Müller B, Ward DM, Chung HY, Morita E, et al. The protein network of HIV budding. Cell 2003; 114:701-713.
30. Alexander L, Weiskopt E, Geenough T, Caddis NC, Auerbach MR, Malim MH, et al. Unusual polymorphisms in HIV-1 associated with non-progressive infection. J Virol 2000; 74:4361-4376.
31. Bates M, Chappey C, Parkin N. Mutations in P6 Gag associated with alterations in replication capacity in drug sensitive HIV-1 are implicated in the budding process mediated bt Tsg101 and AIP1. In: 11th Conference on Retroviruses and Opportunistic Infections. Boston 2004 [Abstract 121].
32. Brondani V, Kirchhoff W, Schefer Q, Klimkait T. Variation of Gag p6 in clinical HIV-1 samples of B and non-B origin: effects on viral fitness and correlation with clinical parameters. In: 3rd Conference on AIDS Pathogenesis and Treatment. Río de Janeiro, Brasil 2005 [Abstract MoPe14.3B04].